$4.18
1.91%
Downside
Day's Volatility :3.98%
Upside
2.11%
70.06%
Downside
52 Weeks Volatility :79.91%
Upside
32.91%
Period | Aquestive Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | 52.0% | 0.0% |
6 Months | -26.41% | 0.0% |
1 Year | 164.56% | 0.0% |
3 Years | -7.11% | -22.3% |
Market Capitalization | 385.6M |
Book Value | - $0.39 |
Earnings Per Share (EPS) | -0.36 |
Wall Street Target Price | 8.81 |
Profit Margin | -44.07% |
Operating Margin TTM | 0.27% |
Return On Assets TTM | -10.88% |
Return On Equity TTM | 0.0% |
Revenue TTM | 58.4M |
Revenue Per Share TTM | 0.79 |
Quarterly Revenue Growth YOY | 51.800000000000004% |
Gross Profit TTM | 28.3M |
EBITDA | -14.0M |
Diluted Eps TTM | -0.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.44 |
EPS Estimate Next Year | -0.49 |
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Next Quarter | -0.12 |
What analysts predicted
Upside of 110.77%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 67.4M | ↑ 0.77% |
Net Income | -61.4M | ↑ 586.3% |
Net Profit Margin | -91.02% | ↓ 77.66% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 52.6M | ↓ 21.98% |
Net Income | -72.7M | ↑ 18.38% |
Net Profit Margin | -138.11% | ↓ 47.09% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 45.8M | ↓ 12.85% |
Net Income | -65.4M | ↓ 10.04% |
Net Profit Margin | -142.56% | ↓ 4.45% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 50.8M | ↑ 10.87% |
Net Income | -90.0M | ↑ 37.75% |
Net Profit Margin | -177.12% | ↓ 34.56% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 47.7M | ↓ 6.2% |
Net Income | -60.2M | ↓ 33.14% |
Net Profit Margin | -126.26% | ↑ 50.86% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 50.6M | ↑ 6.09% |
Net Income | -7.9M | ↓ 86.93% |
Net Profit Margin | -15.56% | ↑ 110.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.1M | ↑ 4.23% |
Net Income | 19.3M | ↓ 206.38% |
Net Profit Margin | 173.4% | ↑ 343.3% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.2M | ↑ 18.92% |
Net Income | -5.8M | ↓ 130.0% |
Net Profit Margin | -43.74% | ↓ 217.14% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.0M | ↓ 1.8% |
Net Income | -2.0M | ↓ 64.87% |
Net Profit Margin | -15.65% | ↑ 28.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.2M | ↑ 1.57% |
Net Income | -8.1M | ↑ 298.57% |
Net Profit Margin | -61.42% | ↓ 45.77% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↓ 8.73% |
Net Income | -12.8M | ↑ 58.16% |
Net Profit Margin | -106.43% | ↓ 45.01% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 20.1M | ↑ 66.76% |
Net Income | -2.7M | ↓ 78.6% |
Net Profit Margin | -13.66% | ↑ 92.77% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 86.9M | ↑ 101.44% |
Total Liabilities | 76.8M | ↑ 10.29% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 78.5M | ↓ 9.64% |
Total Liabilities | 84.6M | ↑ 10.2% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 62.9M | ↓ 19.87% |
Total Liabilities | 111.4M | ↑ 31.65% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 62.0M | ↓ 1.42% |
Total Liabilities | 144.1M | ↑ 29.4% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 55.7M | ↓ 10.19% |
Total Liabilities | 174.2M | ↑ 20.89% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 57.4M | ↑ 3.13% |
Total Liabilities | 163.9M | ↓ 5.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 61.3M | ↑ 10.08% |
Total Liabilities | 170.5M | ↓ 2.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 57.0M | ↓ 7.0% |
Total Liabilities | 163.6M | ↓ 4.03% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 59.4M | ↑ 4.31% |
Total Liabilities | 162.4M | ↓ 0.78% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 57.4M | ↓ 3.41% |
Total Liabilities | 163.9M | ↑ 0.94% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 129.5M | ↑ 125.58% |
Total Liabilities | 165.8M | ↑ 1.17% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 117.6M | ↓ 9.2% |
Total Liabilities | 153.1M | ↓ 7.68% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.0M | ↓ 323.06% |
Investing Cash Flow | -1.8M | ↓ 11.8% |
Financing Cash Flow | 58.0M | ↑ 1214.79% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -60.2M | ↑ 363.47% |
Investing Cash Flow | -663.0K | ↓ 63.65% |
Financing Cash Flow | 49.6M | ↓ 14.53% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -45.5M | ↓ 24.5% |
Investing Cash Flow | -517.0K | ↓ 22.02% |
Financing Cash Flow | 28.5M | ↓ 42.63% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.0M | ↓ 27.45% |
Investing Cash Flow | -913.0K | ↑ 76.6% |
Financing Cash Flow | 30.1M | ↑ 5.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.8M | ↑ 4.38% |
Investing Cash Flow | -2.0K | ↑ 0.0% |
Financing Cash Flow | -9.2M | ↓ 4612.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↓ 189.69% |
Investing Cash Flow | -826.0K | ↑ 41200.0% |
Financing Cash Flow | 4.3M | ↓ 146.57% |
Sell
Neutral
Buy
Aquestive Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Aquestive Therapeutics Inc | 21.87% | -26.41% | 164.56% | -7.11% | 24.4% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Aquestive Therapeutics Inc | NA | NA | NA | -0.44 | 0.0 | -0.11 | NA | -0.39 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Aquestive Therapeutics Inc | Buy | $385.6M | 24.4% | NA | -44.07% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Insights on Aquestive Therapeutics Inc
Revenue is up for the last 2 quarters, 12.05M → 20.09M (in $), with an average increase of 40.0% per quarter
Netprofit is up for the last 2 quarters, -12.82M → -2.74M (in $), with an average increase of 367.3% per quarter
Bratton Capital Management, L.P.
VR Adviser, LLC
BlackRock Inc
Vanguard Group Inc
Franklin Resources Inc
Renaissance Technologies Corp
aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.
Organization | Aquestive Therapeutics Inc |
Employees | 135 |
CEO | Mr. Daniel Barber |
Industry | Health Technology |
A Spac I Acquisition Corp
$4.18
-1.18%
Keyarch Acquisition Corp
$4.18
-1.18%
Connexa Sports Technologies Inc
$4.18
-1.18%
Us Value Etf
$4.18
-1.18%
First Wave Biopharma Inc
$4.18
-1.18%
Global X Msci Next Emerging
$4.18
-1.18%
Fat Projects Acquisition Corp
$4.18
-1.18%
Capital Link Global Fintech
$4.18
-1.18%
Applied Uv Inc
$4.18
-1.18%